The BioFocus website uses cookies to store information on your computer, to improve our website. One of the cookies we use is essential for parts of the site to operate and has already been set. You may delete and block all cookies from this site, but parts of the site will not work. To find out more about the cookies we use and how to delete them, see our privacy notice.


I accept cookies from this site
 

In this section

Filter by year:

Events


Newsletters

Get in contact with us








Back

News & events

BioFocus signs compound management agreement with eMolecules, Inc.

Fri 08 Oct 2010
BioFocus signs compound management agreement with eMolecules, Inc.

BioFocus, a leading provider of integrated gene-to-clinical candidate drug discovery services and eMolecules, Inc., the creators of the open-access chemical structure search engine, today announced that they have signed a compound management service agreement.  Under the agreement eMolecules has selected Compound Focus, Inc., the BioFocus compound management operation located in South San Francisco, as its preferred partner for client compound order aggregation services.

Clients that order compounds from multiple vendors through the eMolecules platform will have the option to ship their compounds directly from the vendor to the Compound Focus facility where both liquid and solid samples will be reformatted into preferred storage containers, passed through analytical quality control and shipped to an agreed client destination. 

“We are pleased to be the chosen partner of eMolecules as they look to bring the business of compound procurement into the 21st century” said Scott Snyder, Senior Director Compound Focus Inc.  “Compound Focus’ full suite of compound management capabilities is well suited to support the broad spectrum of our client requirements” said Klaus Gubernator, CEO of eMolecules.

About BioFocus

BioFocus aims to expand its partners’ drug pipelines by accelerating the gene-to-clinical candidate discovery process.  This is achieved through a comprehensive discovery platform, which includes target discovery in human primary cells, focused as well as diverse compound libraries, in vitro and cell-based screening, structural biology, medicinal chemistry, ADME/PK services, supported by unique chemogenomic and informatics tools, and compound library acquisition, storage and distribution services.  As a service division of Galapagos BioFocus has over 250 employees based in the UK, the US and Switzerland.

About eMolecules

eMolecules, Inc. has created the world's leading open-access chemical structure search engine at www.emolecules.com.  It has rapidly become the world's most popular chemistry web site, distinguished by fast results, ease of use, and up-to-date information about commercially available chemicals.  eMolecules provides chemistry eCommerce solutions for suppliers of research chemicals and industrial and academic research organizations.  For more information, visit eMolecules. 






Print to HTML Print as PDF Send to a friend




BioFocus®, SoftFocus®, Galapagos®, SilenceSelect® and FLeXSelect® ThemePair™, FieldFocus™, HDRA™. Helical Domain Recognition Analysis™, 2D Roadmap™, Thematic Analysis™, SFK™, SFI™, SFG™ and PrimePath™ are trademarks of Galapagos NV and/or its affiliates.